{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-099345","form_type":"8-K","ticker":"REGN","cik":"0000872589","company_name":"REGENERON PHARMACEUTICALS, INC.","filed_at":"2023-09-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.831376+00:00","generated_at":"2026-06-10T22:25:52.587558+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Regeneron CFO Landry to retire Feb 2024; Fenimore named successor; two new directors elected","bullets":["Director Marc Tessier-Lavigne retired Sept 1, 2023 due to potential conflicts with other roles.","CFO Robert E. Landry to retire in Feb 2024; Christopher Fenimore (SVP, Controller) to succeed him.","Board elected Kathryn Guarini as Class III director and David Schenkein as Class II director effective Sept 8, 2023.","Both new directors appointed to Audit (Guarini) and Technology (Schenkein) committees.","No disagreements cited for Landry departure; new directors hold office until 2024 annual meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-099345","json":"https://secwatch.observer/filing/0001104659-23-099345.json","markdown":"https://secwatch.observer/filing/0001104659-23-099345.md","text":"https://secwatch.observer/filing/0001104659-23-099345.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/872589/000110465923099345/0001104659-23-099345-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/872589/000110465923099345/tm2325712d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T22:25:52.587558+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1d1fbb4ac8","claim":"Marc Tessier-Lavigne retired as Director at REGENERON PHARMACEUTICALS, INC..","evidence_excerpt":"On September 1, 2023, Marc Tessier-Lavigne, Ph.D. notified Regeneron Pharmaceuticals, Inc. (“ Regeneron ” or the “ Company ”) of his decision to retire, effective as of that date, as a director of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/872589/000110465923099345/0001104659-23-099345-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"retired"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"c35850bc03","claim":"Robert E. Landry departed as Executive Vice President, Finance and Chief Financial Officer at REGENERON PHARMACEUTICALS, INC..","evidence_excerpt":"On September 8, 2023, Robert E. Landry notified the Company of his intention to retire from his position as Executive Vice President, Finance and Chief Financial Officer of the Company in February 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/872589/000110465923099345/0001104659-23-099345-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"intends to retire"},{"label":"Role","value":"Executive Vice President, Finance and Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"de9df9fcb6","claim":"David P. Schenkein was elected as Class II Director at REGENERON PHARMACEUTICALS, INC..","evidence_excerpt":"Regeneron’s board of directors (the “ Board ”) elected Kathryn Guarini, Ph.D. as a Class III director and David P. Schenkein, M.D. as a Class II director to fill the two vacancies on the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/872589/000110465923099345/0001104659-23-099345-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"Class II Director"}],"fact_type":"executive_change"},{"claim_id":"e5bbc2ee35","claim":"Kathryn Guarini was elected as Class III Director at REGENERON PHARMACEUTICALS, INC..","evidence_excerpt":"Regeneron’s board of directors (the “ Board ”) elected Kathryn Guarini, Ph.D. as a Class III director and David P. Schenkein, M.D. as a Class II director to fill the two vacancies on the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/872589/000110465923099345/0001104659-23-099345-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"Class III Director"}],"fact_type":"executive_change"},{"claim_id":"eb511dd872","claim":"Christopher Fenimore was appointed as Chief Financial Officer at REGENERON PHARMACEUTICALS, INC..","evidence_excerpt":"The Company intends to appoint Christopher Fenimore, currently the Company’s Senior Vice President, Controller, to succeed Mr. Landry as Chief Financial Officer of the Company effective upon Mr. Landry’s retirement.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/872589/000110465923099345/0001104659-23-099345-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}